352 related articles for article (PubMed ID: 10950851)
1. Metabolism of ezlopitant, a nonpeptidic substance P receptor antagonist, in liver microsomes: enzyme kinetics, cytochrome P450 isoform identity, and in vitro-in vivo correlation.
Obach RS
Drug Metab Dispos; 2000 Sep; 28(9):1069-76. PubMed ID: 10950851
[TBL] [Abstract][Full Text] [Related]
2. Cytochrome P450-catalyzed metabolism of ezlopitant alkene (CJ-12,458), a pharmacologically active metabolite of ezlopitant: enzyme kinetics and mechanism of an alkene hydration reaction.
Obach RS
Drug Metab Dispos; 2001 Jul; 29(7):1057-67. PubMed ID: 11408374
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics of ezlopitant, a novel non-peptidic neurokinin-1 receptor antagonist in preclinical species and metabolite kinetics of the pharmacologically active metabolites.
Reed-Hagen AE; Tsuchiya M; Shimada K; Wentland JA; Obach RS
Biopharm Drug Dispos; 1999 Dec; 20(9):429-39. PubMed ID: 10951432
[TBL] [Abstract][Full Text] [Related]
4. Characterization of human cytochrome P450 isoenzymes involved in the metabolism of vinorelbine.
Beulz-Riché D; Grudé P; Puozzo C; Sautel F; Filaquier C; Riché C; Ratanasavanh D
Fundam Clin Pharmacol; 2005 Oct; 19(5):545-53. PubMed ID: 16176333
[TBL] [Abstract][Full Text] [Related]
5. Mechanism of cytochrome P4503A4- and 2D6-catalyzed dehydrogenation of ezlopitant as probed with isotope effects using five deuterated analogs.
Obach RS
Drug Metab Dispos; 2001 Dec; 29(12):1599-607. PubMed ID: 11717179
[TBL] [Abstract][Full Text] [Related]
6. Demethylation of radiolabelled dextromethorphan in rat microsomes and intact hepatocytes.
Di Marco A; Yao D; Laufer R
Eur J Biochem; 2003 Sep; 270(18):3768-77. PubMed ID: 12950260
[TBL] [Abstract][Full Text] [Related]
7. Human reductive halothane metabolism in vitro is catalyzed by cytochrome P450 2A6 and 3A4.
Spracklin DK; Thummel KE; Kharasch ED
Drug Metab Dispos; 1996 Sep; 24(9):976-83. PubMed ID: 8886607
[TBL] [Abstract][Full Text] [Related]
8. The aliphatic oxidation of salmeterol to alpha-hydroxysalmeterol in human liver microsomes is catalyzed by CYP3A.
Manchee GR; Eddershaw PJ; Ranshaw LE; Herriott D; Park GR; Bayliss MK; Tarbit MH
Drug Metab Dispos; 1996 May; 24(5):555-9. PubMed ID: 8723736
[TBL] [Abstract][Full Text] [Related]
9. Identification of the human cytochrome P450s responsible for the in vitro metabolism of a leukotriene B4 receptor antagonist, CP-195,543.
Khojasteh-Bakht SC; Rossulek MI; Fouda HG; Prakash C
Xenobiotica; 2003 Dec; 33(12):1201-10. PubMed ID: 14742142
[TBL] [Abstract][Full Text] [Related]
10. Significance of metabolism in the disposition and action of the antidysrhythmic drug, dofetilide. In vitro studies and correlation with in vivo data.
Walker DK; Alabaster CT; Congrave GS; Hargreaves MB; Hyland R; Jones BC; Reed LJ; Smith DA
Drug Metab Dispos; 1996 Apr; 24(4):447-55. PubMed ID: 8801060
[TBL] [Abstract][Full Text] [Related]
11. Species difference in stereoselective involvement of CYP3A in the mono-N-dealkylation of disopyramide.
Zhang L; Fitzloff JF; Engel LC; Cook CS
Xenobiotica; 2001 Feb; 31(2):73-83. PubMed ID: 11407536
[TBL] [Abstract][Full Text] [Related]
12. Identification of human cytochrome P450 isoforms involved in the 3-hydroxylation of quinine by human live microsomes and nine recombinant human cytochromes P450.
Zhao XJ; Yokoyama H; Chiba K; Wanwimolruk S; Ishizaki T
J Pharmacol Exp Ther; 1996 Dec; 279(3):1327-34. PubMed ID: 8968357
[TBL] [Abstract][Full Text] [Related]
13. Cytochrome P450 isoform inhibitors as a tool for the investigation of metabolic reactions catalyzed by human liver microsomes.
Bourrié M; Meunier V; Berger Y; Fabre G
J Pharmacol Exp Ther; 1996 Apr; 277(1):321-32. PubMed ID: 8613937
[TBL] [Abstract][Full Text] [Related]
14. Characterization of metabolites of a NK1 receptor antagonist, CJ-11,972, in human liver microsomes and recombinant human CYP isoforms by liquid chromatography/tandem mass spectrometry.
Prakash C; Lin J; Colizza K; Miao Z
Rapid Commun Mass Spectrom; 2007; 21(17):2822-32. PubMed ID: 17661339
[TBL] [Abstract][Full Text] [Related]
15. Kinetic analysis of the activation of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone by heterologously expressed human P450 enzymes and the effect of P450-specific chemical inhibitors on this activation in human liver microsomes.
Patten CJ; Smith TJ; Murphy SE; Wang MH; Lee J; Tynes RE; Koch P; Yang CS
Arch Biochem Biophys; 1996 Sep; 333(1):127-38. PubMed ID: 8806763
[TBL] [Abstract][Full Text] [Related]
16. Impact of nonspecific binding to microsomes and phospholipid on the inhibition of cytochrome P4502D6: implications for relating in vitro inhibition data to in vivo drug interactions.
Margolis JM; Obach RS
Drug Metab Dispos; 2003 May; 31(5):606-11. PubMed ID: 12695349
[TBL] [Abstract][Full Text] [Related]
17. Nonspecific binding to microsomes: impact on scale-up of in vitro intrinsic clearance to hepatic clearance as assessed through examination of warfarin, imipramine, and propranolol.
Obach RS
Drug Metab Dispos; 1997 Dec; 25(12):1359-69. PubMed ID: 9394025
[TBL] [Abstract][Full Text] [Related]
18. (R)-, (S)-, and racemic fluoxetine N-demethylation by human cytochrome P450 enzymes.
Margolis JM; O'Donnell JP; Mankowski DC; Ekins S; Obach RS
Drug Metab Dispos; 2000 Oct; 28(10):1187-91. PubMed ID: 10997938
[TBL] [Abstract][Full Text] [Related]
19. Metabolism and effect of para-toluene-sulfonamide on rat liver microsomal cytochrome P450 from in vivo and in vitro studies.
Zhou JQ; Tang ZQ; Zhang JN; Tang JC
Acta Pharmacol Sin; 2006 May; 27(5):635-40. PubMed ID: 16626521
[TBL] [Abstract][Full Text] [Related]
20. Biosynthesis of an aminopiperidino metabolite of irinotecan [7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecine] by human hepatic microsomes.
Haaz MC; Riché C; Rivory LP; Robert J
Drug Metab Dispos; 1998 Aug; 26(8):769-74. PubMed ID: 9698291
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
